216 related articles for article (PubMed ID: 27251777)
1. Distinct genetic profiles of extracranial and intracranial acral melanoma metastases.
Sharma G; Lian CG; Lin WM; Amin-Mansour A; Jané-Valbuena J; Garraway L; Bao W; Yoon CH; Ibrahim N
J Cutan Pathol; 2016 Oct; 43(10):884-91. PubMed ID: 27251777
[TBL] [Abstract][Full Text] [Related]
2. Altered expression and new mutations in DNA mismatch repair genes MLH1 and MSH2 in melanoma brain metastases.
Korabiowska M; König F; Verheggen R; Schlott T; Cordon-Cardo C; Romeike B; Brinck U
Anticancer Res; 2004; 24(2B):981-6. PubMed ID: 15161053
[TBL] [Abstract][Full Text] [Related]
3. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
4. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
Frankel TL; Vakiani E; Nathan H; DeMatteo RP; Kingham TP; Allen PJ; Jarnagin WR; Kemeny NE; Solit DB; D'Angelica MI
Cancer; 2017 Feb; 123(4):568-575. PubMed ID: 27737491
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of human cutaneous melanoma-derived cell lines.
Ogbah Z; Puig-Butille JA; Simonetta F; Badenas C; Cervera R; Milá J; Benitez D; Malvehy J; Vilella R; Puig S
Anticancer Res; 2012 Apr; 32(4):1245-51. PubMed ID: 22493355
[TBL] [Abstract][Full Text] [Related]
6. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
[TBL] [Abstract][Full Text] [Related]
7. The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence.
Rabbie R; Ferguson P; Wong K; Couturier DL; Moran U; Turner C; Emanuel P; Haas K; Saunus JM; Davidson MR; Lakhani SR; Shivalingam B; Long GV; Parkinson C; Osman I; Scolyer RA; Corrie P; Adams DJ
Br J Cancer; 2021 Jan; 124(1):156-160. PubMed ID: 33024263
[TBL] [Abstract][Full Text] [Related]
8. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
[TBL] [Abstract][Full Text] [Related]
9. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
10. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
[TBL] [Abstract][Full Text] [Related]
11. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target.
Chen G; Chakravarti N; Aardalen K; Lazar AJ; Tetzlaff MT; Wubbenhorst B; Kim SB; Kopetz S; Ledoux AA; Gopal YN; Pereira CG; Deng W; Lee JS; Nathanson KL; Aldape KD; Prieto VG; Stuart D; Davies MA
Clin Cancer Res; 2014 Nov; 20(21):5537-46. PubMed ID: 24803579
[TBL] [Abstract][Full Text] [Related]
13. NRAS mutation status is an independent prognostic factor in metastatic melanoma.
Jakob JA; Bassett RL; Ng CS; Curry JL; Joseph RW; Alvarado GC; Rohlfs ML; Richard J; Gershenwald JE; Kim KB; Lazar AJ; Hwu P; Davies MA
Cancer; 2012 Aug; 118(16):4014-23. PubMed ID: 22180178
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.
Peterson LM; Kipp BR; Halling KC; Kerr SE; Smith DI; Distad TJ; Clayton AC; Medeiros F
Int J Gynecol Pathol; 2012 May; 31(3):195-205. PubMed ID: 22498935
[TBL] [Abstract][Full Text] [Related]
15. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival.
Akslen LA; Angelini S; Straume O; Bachmann IM; Molven A; Hemminki K; Kumar R
J Invest Dermatol; 2005 Aug; 125(2):312-7. PubMed ID: 16098042
[TBL] [Abstract][Full Text] [Related]
16. [Immunophenotypes and gene mutations in colorectal precancerous lesions and adenocarcinoma].
Huang WT; Qiu T; Ling Y; Shi SS; Guo L; Zheng B; Lü N; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2013 Oct; 42(10):655-9. PubMed ID: 24433726
[TBL] [Abstract][Full Text] [Related]
17. Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
Reggiani Bonetti L; Barresi V; Bettelli S; Caprera C; Manfredini S; Maiorana A
Hum Pathol; 2017 Apr; 62():91-98. PubMed ID: 28025078
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
19. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations.
Bucheit AD; Chen G; Siroy A; Tetzlaff M; Broaddus R; Milton D; Fox P; Bassett R; Hwu P; Gershenwald JE; Lazar AJ; Davies MA
Clin Cancer Res; 2014 Nov; 20(21):5527-36. PubMed ID: 25165098
[TBL] [Abstract][Full Text] [Related]
20. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.
Rigter LS; Snaebjornsson P; Rosenberg EH; Atmodimedjo PN; Aleman BM; Ten Hoeve J; Geurts-Giele WR; ; van Ravesteyn TW; Hoeksel J; Meijer GA; Te Riele H; van Leeuwen FE; Dinjens WN; van Leerdam ME
Gut; 2018 Mar; 67(3):447-455. PubMed ID: 29439113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
